Known targets — ChEMBL curated mechanism
ADRB1ADRB2ATP4AATP4BAXLCHRM2CHRM3DRD2FLT3HRH1HTR2AHTR2BHTR2CKCNH2KMT2AMAP2K1MAP2K2MEN1MLNRPLK4RENS1PR1SLC6A2SLC6A4atpAatpBatpCatpDatpEatpFatpFHatpGpol
The experimentally established mechanism targets of Fumaric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Maleic Acid SCHEMBL29849281 | 1.00 | TLR7 (0.60) | TLR7TLR8 | |
| Fumaric Acid SCHEMBL673090 | 1.00 | TLR7 (0.60) | TLR7TLR8 | |
| SCHEMBL673448 | 0.92 | TLR7 (0.69) | TLR7TLR8 | |
| SCHEMBL22301797 | 0.87 | TLR7 (0.57) | TLR7TLR8 | |
| SCHEMBL18236338 | 0.87 | TLR7 (0.60) | TLR7TLR8 | |
| SCHEMBL16306624 | 0.86 | TLR7 (0.58) | TLR7TLR8 | |
| SCHEMBL19132216 | 0.85 | TLR7 (0.63) | TLR7TLR8 | |
| SCHEMBL16306619 | 0.85 | TLR7 (0.55) | TLR7TLR8 | |
| SCHEMBL23430757 | 0.84 | TLR7 (0.56) | TLR7TLR8 | |
| SCHEMBL19131056 | 0.84 | TLR7 (0.57) | TLR7TLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12201688-B2 | Lipidated immune response modifier compound compositions, formulations, and methods | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY (US) | 2025-01-21 | — | — | US | disclosed |
| US-20240252617-A1 | CORONAVIRUS SPIKE PROTEIN DESIGNS, COMPOSITIONS AND METHODS FOR THEIR USE | DUKE UNIVERSITY | 2024-08-01 | — | — | US | disclosed |
| EP-4291569-A1 | CORONAVIRUS SPIKE PROTEIN DESIGNS, COMPOSITIONS AND METHODS FOR THEIR USE | Duke University (US) | 2023-12-20 | — | — | EP | disclosed |
| US-20230090437-A1 | LIPIDATED IMMUNE RESPONSE MODIFIER COMPOUND COMPOSITIONS, FORMULATIONS, AND METHODS | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY | 2023-03-23 | — | — | US | disclosed |
| EP-3222621-B1 | LIPIDATED IMMUNE RESPONSE MODIFIER COMPOUND AND ITS MEDICAL USE | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2023-03-08 | — | — | EP | disclosed |
| US-11524071-B2 | Lipidated immune response modifier compound compositions, formulations, and methods | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2022-12-13 | — | — | US | disclosed |
| WO-2022173940-A1 | CORONAVIRUS SPIKE PROTEIN DESIGNS, COMPOSITIONS AND METHODS FOR THEIR USE | DUKE UNIVERSITY (US) | 2022-08-18 | — | — | WO | disclosed |
| US-20210038713-A1 | LIPIDATED IMMUNE RESPONSE MODIFIER COMPOUND COMPOSITIONS, FORMULATIONS, AND METHODS | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY | 2021-02-11 | — | — | US | disclosed |
| US-10821176-B2 | Lipidated immune response modifier compound compositions, formulations, and methods | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2020-11-03 | — | — | US | disclosed |
| US-20200030441-A1 | Lipidated Immune Response Modifier Compound Compositions, Formulations, and Methods | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY | 2020-01-30 | — | — | US | disclosed |
| US-20170333553-A1 | LIPIDATED IMMUNE RESPONSE MODIFIER COMPOUND COMPOSITIONS, FORMULATIONS, AND METHODS | 3M INNOVATIVE PROPERTIES CO (US) | 2017-11-23 | — | — | US | disclosed |
| US-9795669-B2 | Lipidated immune response modifier compound compositions, formulations, and methods | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2017-10-24 | — | — | US | disclosed |
| EP-3222621-A1 | LIPIDATED IMMUNE RESPONSE MODIFIER COMPOUND AND ITS MEDICAL USE | 3M Innovative Properties Company (US) | 2017-09-27 | — | — | EP | disclosed |
| US-20170189521-A1 | LIPIDATED IMMUNE RESPONSE MODIFIER COMPOUND COMPOSITIONS, FORMULATIONS, AND METHODS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2017-07-06 | — | — | US | disclosed |
| EP-2606047-B1 | LIPIDATED IMMUNE RESPONSE MODIFIER COMPOUND COMPOSITIONS, FORMULATIONS, AND METHODS | 3M INNOVATIVE PROPERTIES CO (US) | 2017-01-25 | — | — | EP | disclosed |
| US-20160175433-A1 | LIPIDATED IMMUNE RESPONSE MODIFIER COMPOUND COMPOSITIONS, FORMULATIONS, AND METHODS | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY | 2016-06-23 | — | — | US | disclosed |
| US-9242980-B2 | Lipidated immune response modifier compound compositions, formulations, and methods | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2016-01-26 | — | — | US | disclosed |
| US-20130230578-A1 | LIPIDATED IMMUNE RESPONSE MODIFIER COMPOUND COMPOSITIONS, FORMULATIONS, AND METHODS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2013-09-05 | — | — | US | disclosed |
| EP-2606047-A1 | LIPIDATED IMMUNE RESPONSE MODIFIER COMPOUND COMPOSITIONS, FORMULATIONS, AND METHODS | 3M Innovative Properties Company (US) | 2013-06-26 | — | — | EP | disclosed |
| WO-2012024284-A1 | LIPIDATED IMMUNE RESPONSE MODIFIER COMPOUND COMPOSITIONS, FORMULATIONS, AND METHODS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2012-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10821176-B2 | Lipidated immune response modifier compound compositions, formulations, and methods | IFNG, MYD88, STING1 | TLR7 56/4885TLR8 101/4885 |
| US-20130230578-A1 | LIPIDATED IMMUNE RESPONSE MODIFIER COMPOUND COMPOSITIONS, FORMULATIONS, AND METHODS | IFNG, MYD88, STING1 | TLR7 56/4885TLR8 101/4885 |
| US-20230090437-A1 | LIPIDATED IMMUNE RESPONSE MODIFIER COMPOUND COMPOSITIONS, FORMULATIONS, AND METHODS | IRF3, IFNG, STING1 | TLR7 38/4885TLR8 94/4885 |
| US-11524071-B2 | Lipidated immune response modifier compound compositions, formulations, and methods | IFNG, IRF3, STING1 | TLR7 79/4885TLR8 136/4885 |
| US-20170333553-A1 | LIPIDATED IMMUNE RESPONSE MODIFIER COMPOUND COMPOSITIONS, FORMULATIONS, AND METHODS | IFNG, MYD88, STING1 | TLR7 56/4885TLR8 101/4885 |
| US-20170189521-A1 | LIPIDATED IMMUNE RESPONSE MODIFIER COMPOUND COMPOSITIONS, FORMULATIONS, AND METHODS | IFNG, MYD88, STING1 | TLR7 56/4885TLR8 101/4885 |
| US-20210038713-A1 | LIPIDATED IMMUNE RESPONSE MODIFIER COMPOUND COMPOSITIONS, FORMULATIONS, AND METHODS | IFNG, IRF3, STING1 | TLR7 79/4885TLR8 136/4885 |
| US-12201688-B2 | Lipidated immune response modifier compound compositions, formulations, and methods | IRF3, IFNG, STING1 | TLR7 38/4885TLR8 94/4885 |
| US-20200030441-A1 | Lipidated Immune Response Modifier Compound Compositions, Formulations, and Methods | IFNG, MYD88, STING1 | TLR7 56/4885TLR8 101/4885 |
| US-20240252617-A1 | CORONAVIRUS SPIKE PROTEIN DESIGNS, COMPOSITIONS AND METHODS FOR THEIR USE | SARS1, CD14, ACE2 | TLR7 2176/4885TLR8 2625/4885 |
| US-20160175433-A1 | LIPIDATED IMMUNE RESPONSE MODIFIER COMPOUND COMPOSITIONS, FORMULATIONS, AND METHODS | MYD88, IFNG, STING1 | TLR7 66/4885TLR8 105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.